Cargando…

Considerations for Phage Therapy Against Mycobacterium abscessus

There is a global increasing number of Mycobacterium abscessus infections, especially pulmonary infections. Reduced therapeutic options exist against this opportunistic pathogen due to its high intrinsic and acquired levels of antibiotic resistance. Phage therapy is a promising afresh therapy, which...

Descripción completa

Detalles Bibliográficos
Autores principales: Senhaji-Kacha, Abrar, Esteban, Jaime, Garcia-Quintanilla, Meritxell
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7847891/
https://www.ncbi.nlm.nih.gov/pubmed/33537013
http://dx.doi.org/10.3389/fmicb.2020.609017
_version_ 1783645013888991232
author Senhaji-Kacha, Abrar
Esteban, Jaime
Garcia-Quintanilla, Meritxell
author_facet Senhaji-Kacha, Abrar
Esteban, Jaime
Garcia-Quintanilla, Meritxell
author_sort Senhaji-Kacha, Abrar
collection PubMed
description There is a global increasing number of Mycobacterium abscessus infections, especially pulmonary infections. Reduced therapeutic options exist against this opportunistic pathogen due to its high intrinsic and acquired levels of antibiotic resistance. Phage therapy is a promising afresh therapy, which uses viruses to lyse bacteria responsible for the infection. Bacteriophages have been recently administered under compassionate use to a 15-year-old patient infected with M. abscessus in combination with antibiotics with excellent results. This mini review highlights different recommendations for future phage administrations such as where to look for new phages, the use of cocktail of mycobacteriophages to broaden phage specificity and to tackle resistance and phage insensitivity due to temperate phages present in bacterial genomes, the combined use of phages and antibiotics to obtain a synergistic effect, the liposomal administration to reach a prolonged effect, intracellular delivery and protection against neutralizing antibodies, and the convenience of using this strategy in patients suffering from cystic fibrosis (CF) since phages are believed to promote immunomodulatory actions and eliminate biofilms.
format Online
Article
Text
id pubmed-7847891
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-78478912021-02-02 Considerations for Phage Therapy Against Mycobacterium abscessus Senhaji-Kacha, Abrar Esteban, Jaime Garcia-Quintanilla, Meritxell Front Microbiol Microbiology There is a global increasing number of Mycobacterium abscessus infections, especially pulmonary infections. Reduced therapeutic options exist against this opportunistic pathogen due to its high intrinsic and acquired levels of antibiotic resistance. Phage therapy is a promising afresh therapy, which uses viruses to lyse bacteria responsible for the infection. Bacteriophages have been recently administered under compassionate use to a 15-year-old patient infected with M. abscessus in combination with antibiotics with excellent results. This mini review highlights different recommendations for future phage administrations such as where to look for new phages, the use of cocktail of mycobacteriophages to broaden phage specificity and to tackle resistance and phage insensitivity due to temperate phages present in bacterial genomes, the combined use of phages and antibiotics to obtain a synergistic effect, the liposomal administration to reach a prolonged effect, intracellular delivery and protection against neutralizing antibodies, and the convenience of using this strategy in patients suffering from cystic fibrosis (CF) since phages are believed to promote immunomodulatory actions and eliminate biofilms. Frontiers Media S.A. 2021-01-18 /pmc/articles/PMC7847891/ /pubmed/33537013 http://dx.doi.org/10.3389/fmicb.2020.609017 Text en Copyright © 2021 Senhaji-Kacha, Esteban and Garcia-Quintanilla. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Senhaji-Kacha, Abrar
Esteban, Jaime
Garcia-Quintanilla, Meritxell
Considerations for Phage Therapy Against Mycobacterium abscessus
title Considerations for Phage Therapy Against Mycobacterium abscessus
title_full Considerations for Phage Therapy Against Mycobacterium abscessus
title_fullStr Considerations for Phage Therapy Against Mycobacterium abscessus
title_full_unstemmed Considerations for Phage Therapy Against Mycobacterium abscessus
title_short Considerations for Phage Therapy Against Mycobacterium abscessus
title_sort considerations for phage therapy against mycobacterium abscessus
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7847891/
https://www.ncbi.nlm.nih.gov/pubmed/33537013
http://dx.doi.org/10.3389/fmicb.2020.609017
work_keys_str_mv AT senhajikachaabrar considerationsforphagetherapyagainstmycobacteriumabscessus
AT estebanjaime considerationsforphagetherapyagainstmycobacteriumabscessus
AT garciaquintanillameritxell considerationsforphagetherapyagainstmycobacteriumabscessus